Skip to main content
SpringerLink
Log in

Hepatitis C

  • Chapter
Principles of Molecular Medicine

Abstract

Hepatitis C virus (HCV) infection infects nearly four million people in the United States alone, is the most common cause of chronic liver disease, and also a common indication for liver transplantation in most of the larger transplant centers in this country. HCV infection is an immensely important public health problem. Rapid scientific advancements have been made in this area and our understanding of the virology, disease pathogenesis, diagnosis, diversity of clinical presentations, natural history, treatment, and prevention is evolving rapidly. This chapter will provide the reader with an update review of the various scientific and clinical aspects of HCV and the associated diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 269.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 349.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Selected References

  • Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999;31:17–24.

    Article  PubMed  Google Scholar 

  • Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C infection: a perspective on long-term outcome. Semin Liv Dis 2000; 20:17–35.

    Article  CAS  Google Scholar 

  • Alter MJ, Kniszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 1994. N Engl J Med 1999;341:556–562.

    Article  PubMed  CAS  Google Scholar 

  • Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001;35:531–537.

    Article  PubMed  CAS  Google Scholar 

  • Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinicaly compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 2000;32:852–858.

    Article  PubMed  CAS  Google Scholar 

  • Berebguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666–678.

    Article  Google Scholar 

  • Bouvier-Alias M, Patel K, Dahari H, et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002;36:211–218.

    Article  PubMed  CAS  Google Scholar 

  • Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41–63.

    PubMed  CAS  Google Scholar 

  • Bukh J, Forns X, Emerson SU, Purcell RH. Studies of hepatitis C virus in chimpanzees and their importance for vaccine development. Intervirology 2001;44:132–142.

    Article  PubMed  CAS  Google Scholar 

  • Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV related chronic disease. MMWR 1998;47(No. RR-19).

    Google Scholar 

  • Comanor L, Hendricks DA. Hepatitis C virus RNA tests: performance attributes and their impact on clinical utility. Expert Rev Mol Diagn 2003;3:689–702.

    Article  PubMed  CAS  Google Scholar 

  • Davis GL, Lau JYN. Choice of appropriate endpoints of response to inter feron-α therapy in chronic hepatitis C virus infection. J Hepatol 1995;22(suppl 1): 110–114.

    PubMed  CAS  Google Scholar 

  • Davis GL, Lau JYN. Factors predictive of response to interferon. Hepatol 1997;26:122S–127S.

    Article  CAS  Google Scholar 

  • Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339: 1493–1499.

    Article  PubMed  CAS  Google Scholar 

  • Di Bisceglie AM, McHutchinson J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology 2002;35:224–231.

    Article  PubMed  Google Scholar 

  • Elbeik T, Surtihadi J, Destree M, et al. Multicenter evaluation of the performance characteritics of the Bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Micro 2004;42:563–569.

    Article  CAS  Google Scholar 

  • Fang JWS, Chow V, Lau JYN. Virology of hepatitis C virus. Semin in Liver Dis 1997; 1:493–514.

    Article  CAS  Google Scholar 

  • Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replcation in non-A, non-B hepatitis. N Engl J Med 1991;325: 98–104.

    Article  PubMed  CAS  Google Scholar 

  • Gish RG. Standards of treatment in chronic hepatitis C. Semin Liver Dis 1999;19:35–47.

    PubMed  CAS  Google Scholar 

  • Gretch DR. Diagnostic tests for hepatitis C. Hepatology 1997;26:43S–47S.

    Article  PubMed  CAS  Google Scholar 

  • Hadziyannis SJ, Sette H Jr, Morgan TR, et al.Pegasys International Study Group. Peginteron alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;1(140):346–355.

    Google Scholar 

  • Hoofnagle JH.Therapy for acute hepatitis C. N Engl J Med 2001;345: 1495–1497.

    Google Scholar 

  • Jonas MM. Hepatitis C in children. In: Hepatitis C, Liang TJ and Hoofnagle JH, eds. Biomed Res Rep. San Diego, CA: Academic Press, 2000, pp. 389–404.

    Google Scholar 

  • Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999;19:157–169.

    PubMed  CAS  Google Scholar 

  • Krajden M, Ziermann R, Khan A, et al. Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the COBAS Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay. J Clin Micro 2002;40:2903–2907.

    Article  CAS  Google Scholar 

  • Lau JYN, Mizokami M, Kolberg JA, et al. Application of six hepatitis C virus subtyping systems to sera of patients with chronic hepatitis C in the United States. J Infect Dis 1995; 171:281–289.

    PubMed  CAS  Google Scholar 

  • Lau JYN, Davis GL, Prescott LE, et al. Distribution of hepatitis C virus genotypes in United States patients with chronic hepatitis C seen in tertiary referral centers. Ann Intern Med 1996;124:868–876.

    PubMed  CAS  Google Scholar 

  • Lau JYN, Standring DN. Development of novel therapies for hepatitis C. In: Hepatitis C, Liang TJ, Hoofnagle JH, eds. Biomed Res Rep 2000: San Diego, CA: Academic Press: pp. 453–467.

    Google Scholar 

  • Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41–52.

    Article  PubMed  CAS  Google Scholar 

  • Lee SG, Antony A, Lee N, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepaitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Micro 2000;38: 4171–4179.

    CAS  Google Scholar 

  • Lindenbach BD, Rice CM. Evasive maneuvers by hepatitis C virus. Hepatology 2003;38:3669–3679.

    Article  Google Scholar 

  • McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485–1492.

    Article  PubMed  CAS  Google Scholar 

  • McHutshinson JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19:57–65.

    Google Scholar 

  • Mizokami M, Gobojori T, Lau JYN. Molecular evolutionary Virology-its application to the study of hepatitis C virus. Gastroenterology 1994;107:1181, 1182.

    PubMed  CAS  Google Scholar 

  • Morishima C, Chung M, Ng KW, et al.Stengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Micro 2004;42:421–425.

    Article  CAS  Google Scholar 

  • National Institutes of Health Consensus Develeopment Conference Statement: Management of Hepatitis C. Hepatology 2002;36(Suppl): S3–S20.

    Google Scholar 

  • Nelson DR, Lau JYN. Host immune response to hepatitis C virus. Viral Hepatitis Reviews 1996;2:37–48.

    Google Scholar 

  • Nelson DR, Marousis CG, Davis GL, et al. The role of hepatitis C virus specific cytotoxic T-lymphocytes in chronic hepatitis C. J Immunol 1997;158:1473–1481.

    PubMed  CAS  Google Scholar 

  • Nelson DR, Lau JYN. Pathogenesis of chronic hepatitis C virus infection. Antiviral Therapy 1998;3:25–35.

    PubMed  CAS  Google Scholar 

  • Pawlotsky JM, Bouvier-Alias M, Hezode C, et al. Standardization of hepatitis C virus RNA quantitation. Hepatology 2000;32:654–659.

    Article  PubMed  CAS  Google Scholar 

  • Pawlotsky JM. Use and interpretation of hepatitis C diagnostic assays. Clin Liver Dis 2003;7:127–137.

    Article  PubMed  Google Scholar 

  • Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349: 825–832.

    Article  PubMed  CAS  Google Scholar 

  • Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998;352:1426–1432.

    PubMed  CAS  Google Scholar 

  • Robert W, McMurray. Hepatitis C-Associated Autoimmune Disorders. Rheumatic Diseases Clinics of North America 1998;24:353–374.

    Article  Google Scholar 

  • Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 2000;242:55–84.

    PubMed  CAS  Google Scholar 

  • Rossi SJ, Wright TL. New developments in the treatment of hepatitis C. Gut 2003;52:756, 757.

    Article  PubMed  CAS  Google Scholar 

  • Robertson B, Myers G, Howard C, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol 1998;143: 2393–2403.

    Article  Google Scholar 

  • Sarrazin C, Hendricks DA, Sedarati F, Zeuzem S. Assessment, by ranscription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon α-2a. J Clin Micro 2002;39:2850–2855.

    Article  Google Scholar 

  • Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992;327:1906–1911.

    Article  PubMed  CAS  Google Scholar 

  • Seeff LB. Natural history of hepatitis C. Am J Med 1999;107:10S–15S.

    Article  PubMed  CAS  Google Scholar 

  • Sherman KE, Rouster SD, Horn PS. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis 2002;35:482–487.

    Article  PubMed  Google Scholar 

  • Simmonds P, Alberti A, Bonino F, et al. Nomenclature of genotypes for hepatitis C virus (correspondence). Hepatology 1994;19: 1321–1324.

    Article  PubMed  CAS  Google Scholar 

  • Shiffman ML. Management of interferon therapy non-responders. Clin Liver Dis 2001;5:1025–1043.

    Article  PubMed  CAS  Google Scholar 

  • Thomas DL, Astemborski J, Rai J, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 34:809–816.

    Google Scholar 

  • Walker MP, Appleby TC, Zhong W, Lau JYN, Hong Z. Hepatitis C virus therapies: current treatments, targets and future perspectives. Antiviral Chem Chemother 2003;14:1–21.

    CAS  Google Scholar 

  • Zignego A, Bréchot C. Extrahepatic Manifestations of HCV Infection: Facts and controversies. J Hepatol 1999;31:369–376.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Managing Director, Roth Capital Partners, Newport Beach, CA

    Johnson Yiu-Nam Lau

  2. Kinex Pharmaceuticals, Buffalo, NY

    Jane Wing-Sang Fang

  3. Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

    Masashi Mizokami

  4. Department of Hepatology and Liver Transplantation, California Pacific Medical Center, San Francisco, CA

    Robert G. Gish

  5. Department of Medicine, Division of Cardiology Carolina Cardiovascular Biology Center, University of California, San Francisco, Gastroenterology Division, Veterans Affairs Medical Center, San Francisco, CA

    Teresa L. Wright

Authors
  1. Johnson Yiu-Nam Lau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane Wing-Sang Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masashi Mizokami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert G. Gish
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Teresa L. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Division of Cardiology Carolina Cardiovascular Biology Center, University of North Carolina School of Medicine, Chapel Hill, NC

    Marschall S. Runge MD, PhD  & Cam Patterson MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc.

About this chapter

Cite this chapter

Lau, J.YN., Fang, J.WS., Mizokami, M., Gish, R.G., Wright, T.L. (2006). Hepatitis C. In: Runge, M.S., Patterson, C. (eds) Principles of Molecular Medicine. Humana Press. https://doi.org/10.1007/978-1-59259-963-9_52

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-963-9_52

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-202-5

  • Online ISBN: 978-1-59259-963-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation